April 29, 2026 · Kidney international · DOI: 10.1016/j.kint.2026.03.017

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis

Listen to this summary

The authors of this study aimed to evaluate the impact of belimumab on biomarker responses and identify predictive biomarkers for kidney response in patients with lupus nephritis. They found that belimumab treatment led to significant reductions in specific immunoglobulins and B cell populations, with certain baseline and early changes in biomarkers, such as IgA and anti-C1q antibodies, correlating with improved kidney responses. These findings suggest that specific biomarkers can help predict the effectiveness of belimumab in treating lupus nephritis.

Brad H Rovin, Richard Furie, Ana Malvar, Cynthia Aranow, Jose M Pego-Reigosa, Elena Zakharova, Andreas Schwarting, Angela R Jones-Leone, Paula Curtis, Beulah Ji, David A Roth, André van Maurik

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play